DISCUS: Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling

Sponsor
St George's, University of London (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04936620
Collaborator
St George's University Hospitals NHS Foundation Trust (Other), St. Mary's University (Other), University of Bristol (Other), Ohio State University (Other), University of Cambridge (Other), University of Oxford (Other), Buckinghamshire Healthcare NHS Trust (Other)
222
2
62

Study Details

Study Description

Brief Summary

QUESTION. Does duroplasty improve outcome after spinal cord injury?

WHAT DO WE STUDY? We will investigate whether performing a surgical procedure called duroplasty improves outcomes after spinal cord injury.

WHY SPINAL CORD INJURY? Spinal cord injury is a devastating condition that causes permanent disability such as paralysis, numbness and loss of bladder and bowel control. Currently, there are no treatments shown to improve outcome after spinal cord injury.

WHAT IS DUROPLASTY? Duroplasty is an operation that involves opening the tough membrane around the cord, called the dura, and stitching a patch of artificial dura to expand the space around the swollen cord.

WHY IS DUROPLASTY BEING STUDIED? Based on our preliminary evidence, we think that the dura causes cord pressure after injury. We have shown in a small study of patients that performing this operation safely and effectively reduces pressure on the injured cord.

WHO IS ELIGIBLE? Adult patients with severe spinal cord injuries in the neck who will have surgery within 72 hours.

WHAT TREATMENT? Those who agree to take part will be allocated by chance (like tossing a coin) to standard treatment or standard treatment plus duroplasty. Some patients will also be asked to take part in a smaller study that involves placing probes at the injury site.

WHERE? We will recruit patients from U.K. Major Trauma Centres. Most assessments will be done in U.K. Spinal Injury Centres. Later on, we may recruit from overseas.

HOW LONG? We aim to recruit 222 - 260 patients over 4 years. Patients will be followed up for a year.

WHAT DO WE ASSESS? Patients will be assessed (using questionnaires and by examination) how well they can use their hands, walk, control their bladder and bowel and their quality of life. Some of these assessments will be repeated at 3, 6 and 12 months after surgery.

WHAT IS THE OPTIONAL MECHANISTIC STUDY? DISCUS includes an optional study for at least 50 patients who will take part in the randomised controlled trial. The aim of the mechanistic study is to determine how duroplasty improves outcome, i.e. whether duroplasty reduces cord compression, improves blood flow to the injured cord perfusion, improves cord metabolism and reduces cord inflammation.

WHAT IS THE OPTIONAL INFORMATION STUDY? For the first two years, a study called QuinteT Recruitment Intervention (QRI) is designed to optimise patient recruitment and informed consent in the trauma setting.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Duroplasty
  • Procedure: Spinal surgery
N/A

Detailed Description

RESEARCH QUESTION: After severe traumatic spinal cord injury (TSCI), does the addition of dural decompression to bony decompression (includes laminectomy) improve muscle strength in the limbs at 6 months, compared with bony decompression alone? BACKGROUND: TSCI is a devastating condition that affects about 1,000 people in the UK annually. Most remain disabled, tetraplegic or wheelchair bound and are dependent on carers with significant cost to patients, carers and the NHS. Surgery aims to reduce spinal deformity, stabilise the spine and achieve bony decompression of the cord. To date, no treatments have been shown to improve outcome.

AIMS / OBJECTIVES: The primary aim is to determine if, in patients with acute, severe TSCI, the addition of dural decompression to bony decompression improves muscle strength. We hypothesise that, after TSCI, the cord swells and is compressed against the dura. Secondary objectives are to assess patient impact i.e. functional outcomes, health related quality of life (HRQoL), complication rates and mortality. Mechanistic sub-studies aim to determine if the addition of duroplasty improves cord perfusion, reduces cord ischaemia and cord inflammation.

METHODS: This is a prospective, phase III, multicentre randomised controlled trial (RCT). We aim to recruit 222 adults with acute, severe cervical TSCI (American spinal injuries association Impairment Scale (AIS) grade A, B or C) who will be randomised 1:1 to undergo bony decompression alone versus bony decompression with duroplasty. Patients and assessors will be blinded to study arm. The primary outcome is change in AIS motor score (AMS) at 6 months compared with admission (Delta-AMS); secondary outcomes will assess function (grasp, walking, urinary + anal sphincters), HRQoL, complications, need for further surgery and mortality, assessed at baseline, 3 months, 6 months and 12 months from randomisation. A subgroup of 50 patients (25 per arm) will also have observational monitoring from the injury site using a pressure probe (intraspinal pressure ISP, spinal cord perfusion pressure SCPP) and microdialysis (MD) catheter (cord metabolism: tissue glucose, lactate, pyruvate, lactate-to-pyruvate ratio (LPR), glutamate, glycerol); cord inflammation: tissue chemokines/cytokines. Patients will be recruited from the 26 UK major trauma centres (MTCs).

TIMELINES FOR DELIVERY: The study duration is 72 months and includes 6 months set-up, 48 months recruitment, 12 months to complete follow-up and 6 months for data analysis and final reporting of results. There will be a formal stop/go review at month 15 (after 9 months of recruitment) to ensure a minimum of 4 sites have been opened and 8 patients randomised. If these targets are met, the trial will recruit for a further 36 months. Data from the pilot will be included in the final analysis.

ANTICIPATED IMPACT AND DISSEMINATION: It is anticipated that the addition of duroplasty to standard of care will improve muscle strength in patients; this has obvious benefits for patients and their carers as well as substantial gains for the NHS and society including economic implications. If this RCT shows that the addition of duroplasty to standard treatment is beneficial, it is anticipated that duroplasty will become standard NHS care in all 26 UK MTCs. Participants will be informed of study findings via the Surgical Intervention Trials Unit (SITU) website and the Spinal Injuries Association (SIA).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
222 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Phase III clinical trial: randomised, controlled, double blind, multi-centre, superiority + Optional mechanistic studyPhase III clinical trial: randomised, controlled, double blind, multi-centre, superiorityOptional mechanistic study
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Participants, some care providers (ie: physiotherapists) and outcome assessor will be blinded.
Primary Purpose:
Treatment
Official Title:
Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling
Anticipated Study Start Date :
Jul 1, 2021
Anticipated Primary Completion Date :
Jan 1, 2026
Anticipated Study Completion Date :
Sep 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Duroplasty

Duroplasty (includes Surgery with Laminectomy)

Procedure: Duroplasty
Expansion Duroplasty

Procedure: Spinal surgery
Spinal surgery including laminectomy

Active Comparator: No duroplasty

No duroplasty (but includes surgery with Laminectomy)

Procedure: Spinal surgery
Spinal surgery including laminectomy

Outcome Measures

Primary Outcome Measures

  1. Change in AIS motor score [6 months versus baseline]

    Change in American Spinal Injury Association Impairment Scale total limb motor score at 6 months

Secondary Outcome Measures

  1. Change in AIS light touch score [6 months versus baseline]

    Change in American Spinal Injury Association Impairment Scale total light touch sensory score

  2. Change in AIS pin prick score [6 months versus baseline]

    Change in American Spinal Injury Association Impairment Scale total pin prick sensory score

  3. Change in AIS grade [6 months versus baseline]

    Change in American Spinal Injury Association grade

  4. CUU-Q [6 moths]

    Capabilities of upper extremity-questionnaire (CUE-Q)

  5. Grip strength [6 months]

    Hand grip strength assessed with dynamometer

  6. WISCI II [6 months]

    Walking Index for Spinal Cord Injury version ii

  7. SCIM III [6 months]

    Spinal Cord Independence Measure version III

  8. SF-36 [3 months, 6 months, 12 months]

    Short Form survey 36

  9. Spinal re-operations [12 months]

    Number of reoperations on spine

  10. Adverse events [12 months]

    Procedure Specific complications and adverse events

  11. Mortality [12 months]

    Mortality

  12. Length of hospital stay [12 months]

    Length of hospital stay

  13. MRI [2 weeks, 6 months]

    Magnetic resonance imaging of cervical spine

  14. Injury site physiology and metabolism (optional) [Up to 5 days after surgery]

    Optional mechanistic study: Mean daily intraspinal pressure, spinal cord perfusion pressure, tissue glucose, lactate, pyruvate, glycerol, glutamate, cytokines measured from the injury site

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age ≥16 years

  2. Severe cervical (C2 - T1) traumatic spinal cord injury (AIS grade A-C)

  3. Deemed to require and be suitable for surgery that includes laminectomy by local surgeon

  4. Surgery within 72 hours of traumatic spinal cord injury

  5. Able to provide informed consent or consultee declaration or proxy consent.

Exclusion Criteria:
  1. Dural tear due to traumatic spinal cord injury

  2. Life-limiting or rehabilitation-restricting co-morbidities

  3. Thoracic or lumbar traumatic spinal cord injury

  4. Other central nervous system disease

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • St George's, University of London
  • St George's University Hospitals NHS Foundation Trust
  • St. Mary's University
  • University of Bristol
  • Ohio State University
  • University of Cambridge
  • University of Oxford
  • Buckinghamshire Healthcare NHS Trust

Investigators

  • Principal Investigator: Marios C Papadopoulos, St George's, University of London, U.K.
  • Principal Investigator: Samira Saadoun, St George's, University of London, U.K.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
St George's, University of London
ClinicalTrials.gov Identifier:
NCT04936620
Other Study ID Numbers:
  • 2021.0056
  • 25573423
First Posted:
Jun 23, 2021
Last Update Posted:
Jun 23, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by St George's, University of London
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 23, 2021